Selected Publications
Guichard SM, Macpherson JS, Mayer I, Reid E, Muir M, Dodds M, Alexander S, Jodrell DI. Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and anti-tumour activity. Eur J Cancer 2008; 44: 310-317.
Patel K, Guichard SM, Jodrell DI. Simultaneous determination of decitabine and vorinostat by liquid chromatography tandem mass spectrometry for clinical studies. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 863: 19-25.
Izquierdo MA, Bowman A, García M, Jodrell D, Martinez M, Pardo B, Gómez J, López-Martin JA, Jimeno J, Germá JR, Smyth JF. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with solid tumors. Clin Cancer Res 2008; 14: 3105-3112.
Guichard SM, Hua ML, Kang P, Macpherson JS, Jodrell DI. Short hairpin RNAs targeting Bcl-xL modulate senescence, apoptosis following SN-38 and irinotecan in a colon cancer model. Cancer Chemother Pharmacol 2007; 60: 651-660.
Aird RE, Thomson M, Macpherson JS, Thurston DE, Jodrell DI, Guichard SM. ABCB1 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative, SJG-136. Pharmacogenomics J 2007; [Epub ahead of print].
Primary Research Publications
2008
Brown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, Aird RE, Vora R, Prabhakar U, Nakada M, Corringham RE, DeWitte M, Sturgeon C, Propper D, Balkwill FR, Smyth JF. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer. Annals of Oncology 2008; 19:1340-6
Camidge DR, Oliver JJ, Skinner C, Attwood B, Nussey F, Jodrell D, Webb DJ. The impact of prognosis without treatment on doctors' and patients' resource allocation decisions and its relevance to new drug recommendation processes. British Journal of Clinical Pharmacology 2008; 65:224-9
Connolly K, Mitter R, Muir M, Jodrell D, Guichard S. Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro. Cancer Chemotherapy and Pharmacology 2008; Nov 26 [E-pub ahead of print]
Guichard SM, Macpherson JS, Mayer I, Reid E, Muir M, Dodds M, Alexander S, Jodrell DI. Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity. European Journal of Cancer 2008; 44:310-7
Izquierdo MA, Bowman A, García M, Jodrell D, Martinez M, Pardo B, G&ocute;mez J, L&ocute;pez-Martin JA, Jimeno J, Germ´ JR, Smyth JF. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors. Clinical Cancer Research 2008; 14:3105-12
Patel K, Guichard SM, Jodrell DI. Simultaneous determination of decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies. Journal of Chromatography B: Analytical Technological and Biomedical Life Sciences 2008; 863:19-25
2007
Guichard SM, Hua ML, Kang P, Macpherson JS, Jodrell DI. Short hairpin RNAs targeting Bcl-xL modulate senescence and apoptosis following SN-38 and irinotecan exposure in a colon cancer model. Cancer Chemother Pharmacol 2007; 60(5):651-660
Joerger M, Huitema ADR, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Calvert H, Boddy AV, Hollema H, Fety R, Van der Vijgh WJF, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers AHGJ, Twelves C, Beijnen JH, Schellens JHM. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: A study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group. Clin Cancer Res 2007; 13(21):6410-6418
Joerger M, Huitema ADR, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Fety R, de Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers AHGJ, Twelves C, Beijnen JH, Schellens JHM. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: A study by the EORTC-PAMM-NDDG. Clin Pharmacokinet 2007; 46(12):1051-1068
Knowles G, Sherwood L, Dunlop MG, Dean G, Jodrell D, McLean C, Preston E. Developing and piloting a nurse-led model of follow-up in the multidisciplinary management of colorectal cancer. Eur J Oncol Nurs 2007; 11(3):212-223
Stark LA, Reid K, Sansom OJ, Din FV, Guichard S, Mayer I, Jodrell DI, Clarke AR, Dunlop MG. Aspirin activates the NF-kappa B signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer. Carcinogenesis 2007; 28(5):968-976
2006
Arnould S, Spanswick VJ, Macpherson JS, Hartley JA, Thurston DE, Jodrell DI, Guichard SM. Time-dependent cytotoxicity induced by SJU-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling. Mol Cancer Ther 2006; 5(6):1602-1609
Guichard SM, Else R, Reid E, Zeitlin B, Aird R, Muir M, Dodds M, Fiebig H, Sadler PJ, Jodrell DI. Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds. Biochem Pharmacol 2006; 71(4):408-415
Habtemariam A, Melchart M, Fernandez R, Parsons S, Oswald IDH, Parkin A, Fabbiani FPA, Davidson JE, Dawson A, Aird RE, Jodrell DI, Sadler PJ. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands. J Med Chem 2006; 49(23):6858-6868
Macpherson JS, Jodrell DI, Guichard SM. Validation of real-time reverse-transcription-polymerase chain reaction for quantification of capecitabine-metabolizing enzymes. Anal Biochem 2006; 350(1):71-80
2005
Camidge R, Reigner B, Cassidy J, Grange S, Abt M, Weidekamm E, Jodrell D. Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. J Clin Oncol 2005; 23(21):4719-4725
Camidge R, Walker A, Oliver JJ, Nussey F, Maxwell S, Jodrell D, Webb DJ. Prognosis without treatment as a modifier in health economic assessments. BMJ 2005; 330(7504):1382-1384
Chau I, Norman AR, Cunningham D, Iveson T, Hill M, Hickish T, Lofts F, Jodrell D, Webb A, Tait D, Ross PJ, Shellito P, Oates JR. Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer. Eur J Cancer 2005; 41(11):1551-1559
Chau I, Norman AR, Cunningham D, Tait D, Ross PJ, Iveson T, Hill M, Hickish T, Lofts F, Jodrell D, Webb A, Oates JR. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005; 16(4):549-557
Guichard SM, Macpherson JS, Thurston DE, Jodrell DI. Influence of P-glycoprotein expression on in vitro cytotoxicity and in vivo antitumour activity of the novel pyrrolobenzodiazepine dimer SJG-136. Eur J Cancer 2005; 41(12):1811-1818
Guichard SM, Mayer I, Jodrell DI. Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies. J Chromatogr B 2005; 826(1-2):232-237
Hayward RL, Schornagel QC, Tente R, Macpherson JC, Aird RE, Guichard S, Habtemariam A, Sadler P, Jodrell DI. Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175. Cancer Chemother Pharmacol 2005; 55(6):577-583
MacKinnon AC, Tufail-Hanif U, Lucas CD, Jodrell D, Haslett C, Sethi T. Expression of V-1A and GRP receptors leads to cellular transformation and increased sensitivity to substance-P analogue-induced growth inhibition. Br J Cancer 2005; 92(3):522-531
Sewell JM, Mayer I, Langdon SP, Smyth JF, Jodrell DI, Guichard SM. The mechanism of action of Kahalalide F: Variable cell permeability in human hepatoma cell lines. Eur J Cancer 2005; 41(11):1637-1644
Twelves C, Wong A, Nowacki MP, Abt M, Burris H, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kroning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schuller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352(26):2696-2704
Wang FY, Habtemariam A, van der Geer EPL, Fernandez R, Melchart M, Deeth RJ, Aird R, Guichard S, Fabbiani FPA, Lozano-Casal P, Oswald IDH, Jodrell DI, Parsons S, Sadler PJ. Controlling ligand substitution reactions of organometallic complexes: Tuning cancer cell cytotoxicity. Proc Natl Acad Sci U S A 2005; 102(51):18269-18274
Wong NACS, Malcomson RDG, Jodrell DI, Groome NP, Harrison DJ, Saunders PTK. ER beta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates. J Pathol 2005; 207(1):53-60
2004
Cummings J, Zelcer N, Allen JD, Yao DG, Boyd G, Maliepaard M, Friedberg TH, Smyth JF, Jodrell DI. Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins. Biochem Pharmacol 2004; 67(1):31-39
Gourley C, Cassidy J, Edwards C, Samuel L, Bisset D, Camboni G, Young A, Boyle D, Jodrell D. A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer. Cancer Chemother Pharmacol 2004; 53(2):95-101
Hayward RL, Macpherson JS, Cummings J, Monia BP, Smyth JF, Jodrell DI. Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: genetic evidence for specificity of the antisense effect. Mol Cancer Ther 2004; 3(2):169-178
Jodrell DI, Evans TRJ, Steward W, Cameron D, Prendiville J, Aschele C, Noberasco C, Lind M, Carmichael J, Dobbs N, Camboni G, Gatti B, De Braud F. Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesopliageal adenocarcinoma. Eur J Cancer 2004; 40(12):1872-1877
Wall L, Talbot DC, Bradbury P, Jodrell DI. A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours. Br J Cancer 2004; 90(4):800-804
2003
Cummings J, Ethell BT, Jardine L, Boyd G, Macpherson JS, Burchell B, Smyth JF, Jodrell DI. Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives. Cancer Res 2003; 63(23):8443-8450
Cummings J, Ritchie A, Butler J, Ward TH, Langdon S. Activity profile of the novel aziridinylbenzoquinones MeDZQ and RH1 in human tumour xenografts. Anticancer Res 2003; 23(5A):3979-3983
Hayward RL, Macpherson JS, Cummings J, Monia BP, Smyth JF, Jodrell DI. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity. Clin Cancer Res 2003; 9(7):2856-2865
Saini A, Norman AR, Cunningham D, Chau I, Hill M, Tait D, Hickish T, Iveson T, Lofts F, Jodrell D, Ross PJ, Oates J. Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer 2003; 88(12):1859-1865
Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, Cassidy J, Jodrell D, Koralewski P, Levine EL, Marschner N, Maroun J, Garcia-Alfonso P, Tujakowski J, Van Hazel G, Wong A, Zaluski J, Twelves C, X-ACT Study Group. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003; 14(12):1735-1743
Waters CM, MacKinnon AC, Cummings J, Tufail-Hanif U, Jodrell D, Haslett C, Sethi T. Increased gastrin-releasing peptide (GRP) receptor expression in tumour cells confers sensitivity to [Arg(6),D-Trp7,9,N(me)Phe(8)]-substance P (6-11)-induced growth inhibition. Br J Cancer 2003; 88(11):1808-1816
2002
Aird RE, Cummings J, Ritchie AA, Muir M, Morris RE, Chen H, Sadler PJ, Jodrell DI. in vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer. Br J Cancer 2002; 86(10):1652-1657
Cummings J, Boyd G, Ethell BT, Macpherson JS, Burchell B, Smyth JF, Jodrell DI. Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation. Biochem Pharmacol 2002; 63(4):607-613
Cummings J, Boyd G, Macpherson JS, Wolf H, Smith G, Smyth JF, Jodrell DI. Factors influencing the cellular accumulation of SN-38 and camptothecin. Cancer Chemother Pharmacol 2002; 49(3):194-200
Cummings J, Ethell BT, Boyd G, Burchell B, Smyth JF, Jodrell DI. Determination of the glucuronide metabolites of the topoisomerase I inhibitors 7-ethyl 10-hydroxycamptothecin (SN-38) and NU/ICRF 505 by high-performance liquid chromatography. Chromatographia 2002; 55(Suppl):S157-S163
te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002; 62(6):1876-1883
Wong NACS, Morris RG, McCondochie A, Bader S, Jodrell DI, Harrison DJ. Cyclin DI overexpression in colorectal carcinoma in vivo is dependent on beta-catenin protein dysregulation, but not k-ras mutation. J Pathol 2002; 197(1):128-135
Other Publications
Peacock AFA, Habtemariam A, Fernandez R, Walland V, Fabbiani FPA, Parsons S, Aird RE, Jodrell DI, Sadler PJ. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions. J Am Chem Soc 2006; 128(5):1739-1748
Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004; 23(16):2934-2949
Calvert H, Jodrell DI, Cassidy J, Harris AL. Efficacy, safety, and cost of new anticancer drugs: pessimistic conclusion was not justified. BMJ 2002; 325(7375):1302-1303
Hayward RL, Smyth JF. Editorial comment on 'A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy' by Schmitt et al. Eur J Cancer 2002; 38(17):2207-2209
